Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Acute Double-Blind Phase	STARTED	Atomoxetine	220
Acute Double-Blind Phase	STARTED	Placebo	225
Acute Double-Blind Phase	COMPLETED	Atomoxetine	115
Acute Double-Blind Phase	COMPLETED	Placebo	130
Acute Double-Blind Phase	NOT COMPLETED	Atomoxetine	105
Acute Double-Blind Phase	NOT COMPLETED	Placebo	95
Extension Open-Label Phase	STARTED	Atomoxetine	111
Extension Open-Label Phase	STARTED	Placebo	129
Extension Open-Label Phase	COMPLETED	Atomoxetine	78
Extension Open-Label Phase	COMPLETED	Placebo	81
Extension Open-Label Phase	NOT COMPLETED	Atomoxetine	33
Extension Open-Label Phase	NOT COMPLETED	Placebo	48

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00510276/flow